Clinical Trial Update: To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the impact of oral flecainide on quality of life in patients with atrial fibrillation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• flecainide (flecainide)

Snippet

Sponsor: MEDA Pharma GmbH & Co. KG | Conditions: Atrial Fibrillation | Phase 4 | Status: COMPLETED